Disclosure of Conflict of Interest
AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Hossein Borghaei, DO, MS, reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co; AbbVie; Amgen, Inc; AstraZeneca Pharmaceuticals LP; Axiom Biotechnologies, Inc; BioNTech; Boehringer Ingelheim; Cantargia AB; Celgene Corp; Daiichi Sankyo Co, Ltd; EMD Serono, Inc; Genentech, Inc; Genmab; GLG Pharma; HUYA Bioscience; Lilly USA; Merck & Co Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc; Pharma Mar, S.A; Regeneron Pharmaceuticals, Inc; and Takeda Oncology. Data and safety monitoring board: Incyte Corp; Takeda Oncology; University of Pennsylvania; and Daiichi Sankyo Co, Ltd. Received income in any amount from: Pfizer, Inc; Bristol-Myers Squibb/Lilly; and Merck/Celgene. Research grant: Millennium Pharmaceuticals, Inc; and Rgenix. Scientific advisory board with stock options: Sonnet BioTherapeutics, Inc. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.
The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.